An adjuvant combination comprising an NKT activator, a CD40 agonist, and optionally an antigen, and its use to induce a synergistic enhancement in cellular immunity
Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.